Profile: Cerus Corp (CERS.O)
17 Nov 2017
Cerus Corporation, incorporated on July 31, 1996, is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company's INTERCEPT Blood System is based on its technology for controlling biological replication and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company's INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company's INTERCEPT Blood System is for use with three blood components: plasma, platelets, and red blood cells.
The Company's platelet system and plasma system employ the same technology. Platelet or plasma components collected from blood donors are transferred into plastic INTERCEPT disposable kits and are mixed with the Company's compound, amotosalen, a small molecule compound, which has an affinity for nucleic acid. The disposable kits are then placed in an illumination device, or illuminator, where the mixture is exposed to ultra-violet A (UVA) light. If pathogens, such as viruses, bacteria or parasites, as well as leukocytes, or white cells, are present in the platelet or plasma components, the energy from the UVA light causes the amotosalen to bond with the nucleic acid. The Company's INTERCEPT Blood System for Platelets and Plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion. The Company's INTERCEPT Blood System for Red Blood Cells is designed to inactivate blood-borne pathogens in red blood cells donated for transfusion.
The Company competes with Grifols S.A., Octapharma AG, MacoPharma International, Kedrion Biopharma and Terumo Corporation.
2550 Stanwell Dr
CONCORD CA 94520-4813
Company Web Links
- BRIEF-Cerus receives IDE approval to initiate phase iii recepi study
- BRIEF-Cerus Corp reports Q3 loss per share $0.12
- BRIEF-Cerus and Kedrion Biopharma enter distribution agreement for full INTERCEPT blood system portfolio
- BRIEF-Cerus announces agreement with transfusion Center of the Community of Madrid
- BRIEF-CERUS ANNOUNCES NATIONAL GERMAN REIMBURSEMENT FOR PATHOGEN INACTIVATED PLATELETS